EGFR and head and neck squamous cell carcinoma: A retrospective meta-analysis of EGFR tyrosine kinase inhibitors (TKI) (erlotinib, gefitinib and lapatinib) in 319 HNSCC patients enrolled in five studies, which included the OSI phase II study of erlotinib, found that the development of skin rash, better performance status, and older age were the only three factors associated with improved treatment benefit (7).